it has been suggested that these proteins in fact function as gradient-dependent, selective urea channels (15) .
Because the majority of urea is produced in the liver, it has been proposed that similar protein-facilitated urea transport may also be required in hepatocytes, to avoid osmotic imbalance in these cells during urea synthesis and to allow rapid urea exit from these cells (32) . Expression of possible urea diffusion facilitators and/or transporters in the liver have been investigated previously and both UT-A and UT-B gene products have been identified (3, 13, 17) . However, the specific localization of expression of these UTs either was not determined or was not consistent with a role of UTs in hepatocyte urea permeability. In contrast, aquaporin-9 (AQP9) is a urea permeable protein that is localized at the basolateral membrane of hepatocytes (5) . This promiscuous neutral solute facilitator was originally isolated in an expression cloning screen searching for a putative liver urea channel and, independently, as a urea-permeable aquaporin, expressed in human leukocytes (11, 32) . AQP9 is critically involved in hepatocyte function for glycerol dependent glucose production (2, 12 ), yet its role in urea release has not been investigated. In this study, we demonstrate that AQP9 constitutes a physiologically relevant hepatocyte urea channel and provide evidence for the existence of a second UT-A-like urea channel in hepatocytes.
MATERIALS AND METHODS
Gavage with L-glutamine. All mice had a C57Bl/6 genetic background and were kept under a 12:12-h light-dark cycle on a standard diet with water ad libitum. AQP9 Ϫ/Ϫ mice were described previously (22) . Before experiments, mice were fasted for 16 -18 h to clear food from the digestive system and to raise AQP9 expression, as was described previously (2, 14) . AQP9 ϩ/ϩ and AQP9 Ϫ/Ϫ mice, respectively, were gavaged with 2 mmol/100 g of body wt L-glutamine diluted in 1 ml normal saline solution or with 1 ml normal saline as a control. Thirty minutes after treatment, plasma and tissue samples were harvested. Blood was sampled from the right ventricle into a heparinized syringe and centrifuged (3,000 g for 5 min) for plasma preparation. Plasma proteins were precipitated with ice-cold 42% perchloric acid. Similarly, tissues were dissected and homogenized in nine volumes of ice-cold 7.8% perchloric acid. Samples were neutralized with potassium hydroxide subsequently. Ammonium ion (NH 4 ϩ ) concentrations were assayed by UV absorbance with an ammonia assay kit (Boehringer Mannheim/R-Biopharm; http://www.r-biopharm.com/) according to the manufacturer's instructions.
High-protein diet. Fourteen days before metabolic cage studies, mice were adjusted to synthetic control diet (C1000, Altromin, http:// www.altromin.de). Mice were placed in metabolic cages with unlimited access to water and food. After 3 days of adaptation, mice received a diet that contained 50% protein (C1001, Altromin). It was considered important to maintain the food texture during the experimental period, to avoid reduced food intake after switching to a high-protein diet. Therefore control diet was prepared by mixing 100 g food powder and 83 g of water and high-protein diet was prepared by mixing 100 g food powder with 125 g of water. Water intake by drinking increased in all experimental groups after switching to the high-protein diet, despite the increased water intake along with this food mixture. High-protein diet values were normalized to dry weight food intake, before analysis. This was based on correlation analyses, suggesting significant correlation between food intake and urea output in individual mice (data not shown). Urine was collected under mineral oil for successive 24-h periods. Mice were killed after 4 days of consuming the high-protein diet. Blood and livers were harvested and processed as described for the gavage studies, and metabolite contents were analyzed by The Clinical Pathology Service Laboratory MRC (Harwell Science and Innovation Campus, Oxfordshire, UK). Blood was centrifuged (3,000 g for 5 min) immediately after collection and plasma was separated and subsequently frozen at Ϫ80°C. After separation from oil, urine was centrifuged at 14,000 g for 5 min and frozen at Ϫ20°C. Urine osmolality was measured on a freezing point depression osmometer (3320, Advanced Instruments, http:// www.aicompanies.com).
All animal procedures were approved by the Danish Council for Animal Ethics of the Ministry of Justice.
Preparation of hepatocyte basolateral membrane vesicles. Vesicles of hepatocyte basolateral plasma membranes were prepared as described previously (2) . Briefly, mice were killed after 18 h of fasting to increase AQP9 expression (2, 14) , livers were removed and residual blood was washed out before homogenization with a Potter-Elvehjem homogenizer (15 strokes at 500 rpm) in ice-cold isolation medium consisting of 220 mM mannitol, 70 mM sucrose, 20 mM Tris·HCl, 1 mM EDTA, and 5 mM EGTA, pH 7.4, and protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mM leupeptin, 1 mM pepstatin A). The homogenate was centrifuged at 500 g for 10 min and the pellet, consisting of nuclei and unbroken cells, was discarded. The supernatant was centrifuged at 8,000 g for 20 min and mitochondria were discarded with the pellet. The supernatant was then centrifuged in subsequent steps at 10,000, 14,000, 18,000, and 100,000 g for 15, 20, 20, and 45 min, respectively. Pellets were collected after each centrifugation step and total protein concentration was assayed by the Lowry method (16) . All centrifugations were carried out at 4°C. The membrane fraction enriched in hepatocyte basolateral membranes was identified both by measuring Na ϩ -K ϩ -ATPase activity (a basolateral marker) by the method of Scharschmidt et al. (25) and by immunoblotting with anti-AQP9 antibodies as described previously (2) . The 10,000 g pellet contained comparable Na ϩ -K ϩ -ATPase activity as previously reported (18) as well as AQP9 immunoreactivity. All chemicals were purchased from SigmaAldrich (www.sigmaaldrich.com).
Stopped-flow light-scattering measurements of membrane permeability. The size of the basolateral membrane vesicles prepared as above was determined by use of a N5 Submicron Particle Size Analyzer (Beckman Coulter; www.beckmancoulter.com) and by transmission electron microscopy. The time course of vesicle volume change was determined from changes in scattered light intensity at 10°C (with the exception of activation energy experiments) at a wavelength of 530 nm on a stopped-flow reaction analyzer (BioLogic MPS-200, Claix, France) that has a 1.6 ms dead time and 99% mixing efficiency in less than 1 ms. Light-scattering experiments were performed as described previously (36) by subjecting vesicles to a 250 mM inwardly directed gradient of urea. The approximate urea permeability coefficient (P urea; cm/s) was computed as described previously (34) , by using the equation
where S/V is the vesicle surface-to-volume ratio and is the exponential time constant fitted to the vesicle swelling phase of the light-scattering time course corresponding to urea entry. To study dimethylurea (DMU) inhibition of urea transport, basolateral membrane vesicles were resuspended in EGTA-and EDTA-free media that included 50 mM DMU. During subsequent stopped-flow light-scattering experiments, membrane vesicles were exposed acutely to hypertonic urea-containing solutions while the DMU concentration was maintained (500 mM urea ϩ 50 mM DMU in isolation medium). In some experiments vesicles were resuspended in EGTA-and EDTAfree media before being incubated for 10 min with 0.5 mM phloretin, in the presence or absence of 50 mM DMU, and vesicle urea permeability was measured by stopped-flow light scattering as above. The Arrhenius activation energy (E a; kcal/mol) of the basolateral membrane transport of urea was calculated from temperature dependence data obtained by stopped-flow light scattering at 10, 20, and 37°C.
RT-PCR expression analyses. Total RNA was isolated from fresh liver or kidney tissue by using TRI Reagent (Invitrogen; www.invitrogen. com), followed by RNeasy extraction (QIAGEN; www.qiagen.com). First-strand synthesis was performed with Super Script II reverse transcriptase (Invitrogen) according to the manufacturers' instructions. Oligonucleotides used for PCR amplifications are provided in Table 1 . Products were amplified in 35 reaction cycles. Quantitative PCR analyses were conducted on a LightCycler480 (Roche, Basel, Switzerland), utilizing GoTaq qPCR Master Mix (Promega; www. promega.com) according to the manufacturer's instructions. Primer efficiencies were determined from twofold sample dilution series and relative quantities of UT-B and AQP9 were calculated, considering primer efficiency, as previously suggested compared with the geometric mean of two verified reference genes, HPRT1 and GAPDH (33) . All utilized oligonucleotides are listed in Table 1 .
Immunoblotting. Mouse erythrocyte plasma membranes were prepared as previously reported (24) . Liver, kidney inner medulla, and outer medulla were homogenized in ice-cold dissection buffer containing 0.3 M sucrose, 25 mM imidazole, 1 nM EDTA, 0.6 mM phenylmethylsulfonyl fluoride, and 9 M leupeptin (pH 7.2). The homogenates were centrifuged at 500 g for 10 min at 4°C. Subsequently, the supernatant was centrifuged at 17,000 g for 30 min at 4°C to produce a pellet enriched for plasma membranes. The pellets were resuspended in dissection buffer and gel samples were prepared by Table 1 . Oligonucleotides used to characterize UT-A and AQP9 expression
addition of sample buffer to a final concentration of 3% SDS. Total protein concentration was determined by use of the BCA protein assay kit (Pierce, Thermo Scientific, Rockford, IL), and equal amounts of protein were loaded for SDS-PAGE. The immunoblotting procedure has been described previously (5). The following previously described primary antibodies and affinity-purified antisera were utilized: UT-A; sera mL446, mQ2, and mL194 (29) as well as L194 (19); mouse monoclonal antibody against the Na ϩ -K ϩ -ATPase ␣1 subunit (8); rabbit anti-rat AQP1 serum (31) . UT-A and Na ϩ -K ϩ -ATPase immunoreactivity was quantified in ImageJ (26) .
In silico UT-A gene structure analysis. The genomic UT-A region (GenBank access gi 149321426:c78793689 -78240353 Mus musculus) was analyzed with the help of GENSCAN (http://genes.mit.edu/ GENSCAN.html) for the presence of cryptic exons. Sequences corresponding to 801 putative exons were assembled in Microsoft Excel with the help of a macro that is available on request. A batch file of these sequences (Supplementary Spreadsheet S1; Supplemental Material for this article is available online at the Journal website) was compared with UT-A1 (NM_207651) by utilizing tblastx (http:// blast.ncbi.nlm.nih.gov/) and the "align two or more sequences" option.
Statistical analysis. One-way ANOVA followed by a Tukey's multiple-comparison test was performed to analyze gavage data as well as plasma and liver values obtained in high-protein diet experiments. Two-way ANOVA followed by Bonferroni posttest was performed to analyze urine values obtained in high-protein diet experiments, whereby multiple values obtained from one mouse where considered as repeated measurements. Light-scattering data were obtained from three to five independent liver preparations. These data were analyzed by Student's t-test. Results were considered statistically significant when P Ͻ 0.05.
RESULTS

Ammonia and urea homeostasis is unaffected in AQP9
Ϫ/Ϫ mice. AQP9 exhibits high urea permeability and is expressed at the hepatocyte basolateral membrane (5, 32) . We therefore hypothesized that urea might accumulate in livers of AQP9 Ϫ/Ϫ mice during urea synthesis. However, under standard dietary conditions, plasma urea levels of AQP9 Ϫ/Ϫ mice and AQP9 ϩ/Ϫ mice are similar (22) . AQP9 Ϫ/Ϫ and AQP9 ϩ/ϩ mice were therefore gavage fed with normal saline or L-glutamine solution. The latter is known to elevate plasma ammonia levels (30) and may provide a preferred substrate for urea synthesis (10) . Ammonia and urea concentrations were measured in plasma and liver of both genotypes. We observed a significant increase in ammonia concentration after L-glutamine loading in liver and plasma samples of both AQP9 Ϫ/Ϫ and AQP9 ϩ/ϩ mice, compared with saline controls. However, no differences between genotypes in plasma or tissue urea concentrations were detected (Fig. 1, A and B) .
To test a possible physiological role of AQP9 during medium term elevation of urea synthesis, AQP9 Ϫ/Ϫ and AQP9 ϩ/ϩ mice were subjected to a high-protein diet (50% protein) for 4 days. This treatment is known to stimulate urea synthesis in rats (21) . Urea and ammonia levels were monitored daily in urine prior to and during this experimental treatment. Plasma and liver values were analyzed after 4 days of high-protein diet. Urine output along with urea and ammonia excretion rose significantly during the high-protein diet, suggesting enhanced urea production (Fig. 2, A-C) . Nevertheless, urinary excretion of urea and ammonia, respectively, was not different between AQP9 Ϫ/Ϫ and AQP9 ϩ/ϩ mice. Similarly, concentrations of analyzed nitrogen metabolites measured in plasma and livers were comparable between genotypes (Fig. 2, D and E) . Furthermore, plasma values of glycerol, triglycerides, free fatty acids, glucose, and ketone bodies were not significantly different between AQP9 Ϫ/Ϫ and AQP9 ϩ/ϩ mice ( Table 2 ). We therefore concluded that either AQP9 is not a functional urea channel in hepatocytes or alternative pathways (these include diffusion through the lipid bilayer) exist that are sufficient for physiologically necessary urea transmembrane movement.
AQP9 functions as a urea channel at the hepatocyte basolateral membrane. To distinguish between these two possibilities, urea permeability was measured in hepatocyte basolateral membrane vesicles (10,000 g membrane fraction) prepared from mouse livers after 18 h of fasting. These conditions generate high hepatic AQP9 expression levels (2, 14) . Similar measurements were performed with vesicles prepared from livers of AQP9 knockout mice. Furthermore, inhibition of vesicle urea permeability was investigated by using phloretin and 1,3-DMU, two known inhibitors of facilitated urea transport (32, 35) . The apparent P urea value of AQP9 Ϫ/Ϫ mouse vesicles was significantly lower than that of AQP9 ϩ/ϩ vesicles (0.96 Ϯ 0.08 vs. 1.38 Ϯ 0.09 ϫ 10 Ϫ5 cm/s, respectively; Fig. 3 ). Furthermore, a 10-min incubation with 0.7 mM phloretin reduced urea permeability in vesicles prepared from both AQP9 Ϫ/Ϫ and AQP9 ϩ/ϩ mice, respectively, albeit to a different extent (66 vs. 87%, respectively; Fig. 3A) . Similarly, DMU inhibited urea permeability of vesicles prepared from AQP9 Ϫ/Ϫ and AQP9 ϩ/ϩ mice. In contrast to phloretin, AQP9 Ϫ/Ϫ and AQP9 ϩ/ϩ mouse vesicles were affected to a similar extent by DMU treatment (Fig. 3A) . There was no additive effect if phlor- Fig. 1 . Effects of force feeding with L-glutamine on tissue ammonia and urea levels. Ammonia (A) and urea (B) concentrations in liver and plasma were determined 30 min after gavage with 2 mmol/100 g body wt of L-glutamine (Gln) in saline. L-Glutamine treatment caused significantly elevated plasma and liver ammonia levels, compared with control saline (sal) treatment (*P Ͻ 0.05). No significant difference was detected between AQP9 ϩ/ϩ and AQP9 Ϫ/Ϫ tissue ammonia and urea concentrations, respectively (P Ͼ 0.05). Mean Ϯ SE values are depicted. AQP9 Ϫ/Ϫ : n ϭ 13 for L-glutamine and n ϭ 10 for saline; AQP9 ϩ/ϩ : n ϭ 14 for L-glutamine and n ϭ 10 for saline.
etin and DMU were applied simultaneously, indicating overlapping molecular inhibitor targets (Fig. 3A) .
The role of AQP9 in liver urea permeability was further addressed by determining the E a of urea transport from temperature dependence data of liver membrane vesicles. Arrhenius plotting of liver P urea values of AQP9 ϩ/ϩ mouse vesicles at 5, 20, and 37°C resulted in an E a of 2.38 kcal/mol (Fig. 3B) . This value suggested that facilitated permeation of urea was observed. By comparison, the E a of AQP9 Ϫ/Ϫ mouse vesicles was higher (5.12 kcal/mol; Fig. 3B ). Together these experiments suggested that AQP9 is a functional urea channel in hepatocytes. However, the low E a of AQP9 Ϫ/Ϫ mouse vesicles together with the inhibitor experiments suggested that additional pathways of facilitated urea transport exist in murine hepatocytes. Inhibition of urea permeability by DMU was consistent with a role of a canonical UT protein in hepatocyte urea permeability.
UT-A1/3 Ϫ/Ϫ mice display reduced basolateral membrane urea permeability. We investigated urea permeability in vesicles prepared from fasted UT-A1/3 Ϫ/Ϫ single-knockout and AQP9
Ϫ/Ϫ double-knockout mice. The extent of the inhibitory effects exerted by phloretin and DMU were also evaluated. The liver P urea of UT-A1/3 Ϫ/Ϫ mice was 40% lower than that of wild-type mice (Fig. 4A) , which indicated an important contribution of UT-A to liver urea permeability. Upon treatment with phloretin, liver P urea of UT-A1/3 Ϫ/Ϫ mice was reduced by 66% whereas no decrease was seen when the vesicles were exposed to DMU (Fig. 4A) . Consistent with these inhibitor profiles, P urea of vesicles prepared from AQP9 Ϫ/Ϫ : UT-A1/3 Ϫ/Ϫ double-knockout mice was 76% lower than P urea of AQP9 ϩ/Ϫ :UT-A1/3 ϩ/Ϫ double-heterozygous mice (Fig. 4B) . No further decrease in urea permeability was seen when the vesicles of AQP9
Ϫ/Ϫ double-knockout mice were incubated with phloretin and/or DMU (Fig. 4B) . To rule out significant contamination of liver membrane preparations with erythrocyte membranes, which contain high levels of UT-B, we tested erythrocyte and liver membranes with anti-AQP1 serum. Immunoblots revealed minute amounts of AQP1 in liver membrane preparations, compared with erythrocyte membranes (Fig. 4C ). Together these experiments suggest that AQP9 and a UT-A gene product constitute the molecular targets of the urea channel inhibitors DMU and phloretin and together account for ϳ80% of hepatocyte basolateral membrane urea permeability.
Known UT-A transcripts are not detectable in murine liver. Expression of UT-A mRNA or protein in mouse, rat, and chimpanzee liver as well as in HepG2 human hepatoma cells has been demonstrated previously (3, 13) . However, the UT-A gene encodes several transcripts and proteins (28) and the expression of a specific transcript in liver of any species has not been demonstrated. UT-A1/3 Ϫ/Ϫ mice were created by replacing mouse UT-A exon 10 with a neomycin cassette (6) . We therefore designed RT-PCR primers that would detect expression of exon 10, but also an array of further oligonucleotides targeting exons 7, 8, and 18 -24, to investigate UT-A expres- Values are means Ϯ SE; n ϭ 9. Fig. 2 . Effect of high-protein diet on urine, plasma, and liver urea and ammonia levels. Urine output (A), urea excretion (B), and ammonia excretion (C) were significantly elevated after high-protein diet implementation (*P Ͻ 0.0001). No significant difference was detected between AQP9 ϩ/ϩ and AQP9 Ϫ/Ϫ urea and ammonia levels in urine (B and C) and tested tissues (D and E) (P Ͼ 0.05). Values are means Ϯ SE (n ϭ 9) and were standardized to dry weight of daily food intake. sion in murine tissues by RT-PCR (Fig. 5 and Table 1 ). We were however, unable to detect expression of UT-A in liver RNA by RT-PCR with these primer sets, while robust expression of all tested regions was detected in kidney cDNA. Furthermore, robust expression of AQP9 was detected in liver RNA, indicating integrity of the liver cDNA preparations (Fig.  5 ). In agreement with these results, previously described antisera raised against four UT-A peptides (MATERIALS AND METH-ODS) yielded no or no specific immunoreactivity to UT-A in liver membrane preparations, as indicated by identical banding patterns in UT-A1/3 ϩ/ϩ and UT-A1/3 Ϫ/Ϫ mice. However, expression of antigens with an apparent molecular weight of ϳ40 -60 kDa was reduced in UT-A1/3 Ϫ/Ϫ kidney outer medulla membrane preparations, compared with wild type. Molecular weight and selective expression of these antigens in outer medulla are consistent with UT-A2 (Fig. 6 and data not shown). Effects of UT-A exon 10 deletion in UT-A1/3 Ϫ/Ϫ mice on UT-A2 expression were not expected, since UT-A2 mRNA initiates 6.5 kb 3= of exon 10. In the mouse genome, the UT-B gene is located immediately downstream of UT-A. We therefore considered that UT-B mRNA might be expressed in mouse liver and that expression could be affected by UT-A exon 10 deletion in UT-A1/3 Ϫ/Ϫ mice. To exclude contamination from erythroblasts that express high amounts of UT-B mRNA, we perfused livers with PBS, before RNA isolation for RT-PCR analyses of UT-B expression. In conventional RT-PCR we found UT-B expression in these preparations (data not shown).
To test whether UT-B downregulation could explain reduced urea permeability in UT-A1/3
Ϫ/Ϫ mice, we determined the level of UT-B as well as AQP9 expression in UT-A1/3 Ϫ/Ϫ mice. We found no significant difference in expression of these two genes between UT-A1/3 Ϫ/Ϫ and UT-A1/3 ϩ/ϩ mice. Furthermore, expression of UT-B was minute compared with AQP9 (Fig. 5, bottom right) . Next we performed in silico analysis of the UT-A genomic region, to detect cryptic exons. GENSCAN analysis detected 801 putative exons in the region examined. However, subsequent sequence comparison between UT-A1 protein and putative in silico translated exons identified no obvious candidates for further analyses by RT-PCR. We therefore concluded that no conventional UT-A transcripts are expressed at a detectable level in murine liver.
Ammonia and urea homeostasis is unaffected in AQP9 Ϫ/Ϫ : UT-A1/3
Ϫ/Ϫ mice. According to our stopped-flow light-scattering studies, simultaneous deletion of AQP9 and UT-A caused an 80% decrease of urea permeability in hepatocyte basolateral membrane vesicles. Therefore, we investigated whether these gene deletions would affect urea homeostasis in mice. AQP9 Ϫ/Ϫ and UT-A1/3 Ϫ/Ϫ as well as AQP9 Ϫ/Ϫ :UT-A1/ 3 Ϫ/Ϫ and control AQP9 ϩ/Ϫ :UT-A1/3 ϩ/Ϫ double heterozygous mice were subjected to a high-protein diet (50%) for 4 days. During permeability studies, mice were starved before vesicle preparations to enhance AQP9 expression (2, 14) . Therefore, we subjected mice to 24 h of starvation during the experimental period. In all experimental groups, urinary output along with urea and ammonia daily excretion rose significantly during the high-protein diet (Fig. 6, A-C) . Consistent with previous observations (6) , UT-A1/3 Ϫ/Ϫ and AQP9 Ϫ/Ϫ :UT-A1/3 Ϫ/Ϫ mice had significantly increased urine volume (Fig. 7A) and reduced urine osmolality (data not shown) compared with AQP9
ϩ/Ϫ and AQP9 Ϫ/Ϫ mice during the whole period Fig. 3 . Urea permeability (Purea) in basolateral membrane vesicles prepared from AQP9 ϩ/ϩ and AQP9 Ϫ/Ϫ mice. Urea transport inhibitors dimethylurea (DMU) and phloretin reduced urea permeability in all preparations (*P Ͻ 0.05). More robust inhibition was observed with phloretin than with DMU. Concomitant application of both inhibitors did not result in additive effects, indicating that the same molecular targets were affected (A). Arrhenius activation energy (Ea) plots of urea transport in hepatocyte basolateral membrane vesicles from wild-type and AQP9 null mice. Urea permeability of hepatocyte basolateral membrane vesicles was evaluated by stopped-flow light scattering. Ea plots were constructed from Purea values measured at 10, 20, and 37°C (B). Data are means Ϯ SE; n ϭ 4. Ϫ/Ϫ and AQP9 ϩ/Ϫ :UT-A1/3 ϩ/Ϫ mice were comparable. However, the measured concentrations of liver and plasma urea were significantly higher in AQP9 Ϫ/Ϫ mice than in controls (Fig. 7, F and G) . This is somewhat in contrast to the experiments shown in Fig. 2 , where no differences between AQP9 ϩ/ϩ and AQP9 Ϫ/Ϫ mice were observed. We presume that the observed increase in plasma and liver urea concentration in
AQP9
Ϫ/Ϫ mice may have resulted from the 24-h starvation and subsequent refeeding regime, which was part of the protocol applied in the experiment shown in Fig. 7 , but not in the one shown in Fig. 2 . However, the measured liver and plasma urea values were comparable (Fig. 7H) . This suggested that no measureable urea gradient between plasma and liver had emerged in AQP9 Ϫ/Ϫ mice under these conditions. We concluded that most likely altered urea synthesis but not impaired hepatocyte urea permeability caused elevated plasma and liver urea concentrations in AQP9 Ϫ/Ϫ mice after starvation and subsequent refeeding of a high-protein diet. (15) . Cassette A1 is highly homologous to A2 and cassette B1 is highly homologous to B2. Homology between cassettes A and B is low and the putative membrane topology of A and B is reversed. Bottom: exon-exon structure of UT-A1 mRNA, along with regions targeted for expression analyses (numbered 1-7). All elements are drawn to scale. Example RT-PCR results are depicted at bottom left. PCR reactions were optimized for detecting low-abundance transcripts, which precludes quantitative interpretations. Numbering is as indicated above. Robust amplification of UT-A transcript fragments was detected in kidney cDNA whereas no amplification products were obtained from liver cDNA templates. In contrast, robust amplification of AQP9 was observed from liver cDNA, indicating template integrity. fed/fast, Liver cDNA template prepared from fed and fasted animals, respectively; kid, whole kidney cDNA used as template; ϩ/Ϫ, reverse transcriptase added/omitted. Note that primer pairs 2, 4 and 6 target a single exon and are therefore expected to amplify genomic DNA traces in the template preparation. Bottom right: relative quantification of AQP9 and UT-B expression in UT-A1/3 ϩ/ϩ and UT-A1/3 Ϫ/Ϫ mice did not reveal differential gene expression between genotypes (P Ͼ 0.05, n ϭ 3). Gene expression values Ex, where x indicates AQP9 or UT-B, were calculated as indicated in the figure, compared with the geometric mean of HPRT1 and GAPDH reference genes. Fig. 6 . Protein expression analysis of UT-A in mouse liver and kidney membrane preparations. Immunoblots of kidney inner medulla (IM), outer medulla (OM), and liver membrane preparations. Anti-UT-A (mL194; top) and anti-Na ϩ -K ϩ -ATPase sera (bottom, 3 different film-exposure times are demarcated by black frames) were utilized for immunodecoration. Interpretations of immunoreactivity are on the basis of previously described observations (29) . Bands consistent with glycosylated UT-A1 were observed in inner medulla (100 and 120 kDa). Densitometry indicated 3. 
DISCUSSION
In mammalian physiology, urea synthesis in hepatocytes is crucial for removing excess nitrogen that can build up in the form of ammonia from the bloodstream. Urea permeability of most biological membranes is moderate, which raised the question whether protein facilitated urea transport from hepatocytes into blood is required to protect these cells from intracellular urea accumulation (32) . Whereas urea channel functions have been well characterized in the kidney, the identification of specific urea transporters or channels in liver has been notoriously difficult. Here, we report for the first time the contribution of a specific molecule, AQP9, to hepatocyte basolateral membrane urea permeability. Furthermore, we present clear functional evidence that, besides AQP9, other, more important protein facilitated pathways for urea transmembrane transport do exist in hepatocytes. In full agreement with a previous study utilizing perfused rat livers and rat hepatocytes (4) we found that murine hepatocytes express urea facilitators that can be inhibited by phloretin and urea analogs. Inhibition of urea permeability by these substances suggested that an alternative pathway may be formed by a UT-like protein. This finding is consistent with previous reports in which UT-A protein and mRNA, albeit no specific isoforms or transcripts, had been detected in rat liver preparations (3, 13) . We observed reduced urea permeability in hepatocyte membranes prepared from UT-A1/3 Ϫ/Ϫ mice, which further implicates a UT-A protein isoform in hepatocyte membrane urea permeability.
The UT-A1/3 Ϫ/Ϫ mice used in this study were created by replacing UT-A exon 10 with a neomycin cassette (6) . We therefore tried to characterize specific UT-A transcripts expressed in mouse hepatocytes, initially by RT-PCR amplification of exon 10. Subsequently, we tried to detect expression of other exons that encode conserved, structurally important UT channel regions. We were, however, unable to detect expression of any considered UT-A transcript region. In addition, a thorough in silico analysis of the UT-A genomic region did not identify likely candidate regions for further UT-A expression analyses. In a previous study, Klein and coworkers (13) detected apparent UT-A immunoreactivity of ϳ36 and ϳ50 kDa in mouse, rat, and chimpanzee liver, as well as in a human liver cell line. In the present study we utilized antisera L194 and mL194 that were raised to the identical and mouse-homologous peptides, respectively, as the serum previously utilized by Klein and coworkers. The results obtained with both sera were similar in our hands and did not identify specific UT-A immunoreactivity in mouse liver that could explain the observed reduced urea permeability in UT-A1/3 Ϫ/Ϫ mice. We emphasize that absolute control of immunoreagent specificity requires knockout animals, which were not available to Klein and coworkers. On the basis of our study, employing knockout mice, we consider it unlikely that anti-UT-A immunoreactivity 
Ϫ/Ϫ , and AQP9 Ϫ/Ϫ mice's urine and tissue urea and ammonia levels. Urine output (A) urine urea levels (B) and urine ammonia levels (C) were significantly higher after high-protein diet treatment in all experimental groups (*P Ͻ 0.0001). UT-A1/3 Ϫ/Ϫ and AQP9 Ϫ/Ϫ :UT-A1/3 Ϫ/Ϫ mice had significantly elevated urinary excretion compared with controls (*P Ͻ 0.05; A). Urea (D) and ammonia (E) levels in urine during fasting at day 3 were not significantly altered between genotypes. No significant differences were detected between AQP9 Ϫ/Ϫ :UT-A1/3 Ϫ/Ϫ and UT-A1/3 Ϫ/Ϫ vs. AQP9 ϩ/Ϫ :UT-A1/3 ϩ/Ϫ urea and ammonia levels (P Ͼ 0.05) in urine (B and C), plasma (F), and liver (G), whereas both plasma (F) and liver (G) urea levels were elevated in AQP9 Ϫ/Ϫ mice compared with AQP9 ϩ/Ϫ :UT-A1/3 ϩ/Ϫ mice (*P Ͻ 0.01). No significant differences in plasma and liver ammonia levels were observed between groups (P Ͼ 0.05). The ratio of liver to plasma urea concentration did neither significantly differ from unity nor between tested genotypes (P Ͼ 0.05; H). AQP9 Ϫ/Ϫ :UT-A1/3 Ϫ/Ϫ (n ϭ 8), AQP9 ϩ/Ϫ :UT-A1/3 ϩ/Ϫ , UT-A1/3 Ϫ/Ϫ , and AQP9 Ϫ/Ϫ (n ϭ 7). Values are means Ϯ SE and were normalized to food intake.
observed by Klein et al. in mouse liver was reflecting UT-A protein expression. Furthermore, we found only minute expression of UT-B in liver, suggesting that UT-B doesn't contribute to hepatocyte urea permeability at a physiologically relevant level. Therefore the molecular nature of (a) putative additional transporter(s), besides AQP9, expressed in murine liver remains unknown.
It was recently demonstrated that AQP9 is expressed most prominently at liver basolateral membranes after 18 h of starvation (2) . Vesicles tested in the present study were prepared from mice treated in this way to maximize visibility of the AQP9 contribution to hepatocyte membrane urea permeability. This suggests that the relative contribution of AQP9 to hepatocyte urea permeability is lower when food is available ad libitum. In contrast, the role of AQP9 in glycerol gluconeogenesis (12) is correlated with enhanced AQP9 expression (2, 14) . Therefore, food-dependent AQP9 expression suggests glycerol gluconeogenesis as the primary role of this channel in hepatocytes, despite high AQP9 urea permeability (32) . Consistent with these considerations, we only observed alterations in urea levels in AQP9 Ϫ/Ϫ mice after these animals had been subjected to starvation and refeeding. We hypothesize that in AQP9 Ϫ/Ϫ mice reduced glycerol gluconeogenesis during fasting required more extensive depletion of other storage pools for maintaining energy homeostasis, e.g., glycogen and skeletal muscle protein. Subsequently, during early phases of refeeding a high-protein diet, this depletion may have been compensated by enhanced utilization of dietary amino acids in gluconeogenesis. Thereby, enhanced urea synthesis would help to avoid ammonia buildup resulting from amino acid deamination and explain the temporarily enhanced urea levels observed in AQP9 Ϫ/Ϫ mouse livers and plasma. This transient urea buildup may have been less visible in AQP9 Ϫ/Ϫ :UT-A1/3 Ϫ/Ϫ mice, because of slightly enhanced urea loss in urine.
In conclusion, our study provides experimental evidence for a role of AQP9 and a larger contribution of a UT-like protein to urea permeability of hepatocyte plasma membranes. However, although AQP9 contributes to removal of urea from the liver, its primary function may be to make glycerol available for gluconeogenesis in hepatocytes.
